Search

Your search keyword '"Y-S Lu"' showing total 504 results

Search Constraints

Start Over You searched for: Author "Y-S Lu" Remove constraint Author: "Y-S Lu"
504 results on '"Y-S Lu"'

Search Results

1. The influence of plant water stress on vegetation–atmosphere exchanges: implications for ozone modelling

2. Optimization of weather forecasting for cloud cover over the European domain using the meteorological component of the Ensemble for Stochastic Integration of Atmospheric Simulations version 1.0

Catalog

Books, media, physical & digital resources

3. Temporal Structures in Positron Spectra and Charge-Sign Effects in Galactic Cosmic Rays

5. Properties of Cosmic-Ray Sulfur and Determination of the Composition of Primary Cosmic-Ray Carbon, Neon, Magnesium, and Sulfur: Ten-Year Results from the Alpha Magnetic Spectrometer

6. Temporal Structures in Electron Spectra and Charge Sign Effects in Galactic Cosmic Rays

7. Properties of Daily Helium Fluxes

8. Periodicities in the Daily Proton Fluxes from 2011 to 2019 Measured by the Alpha Magnetic Spectrometer on the International Space Station from 1 to 100 GV

9. Properties of a New Group of Cosmic Nuclei: Results from the Alpha Magnetic Spectrometer on Sodium, Aluminum, and Nitrogen

10. Properties of Heavy Secondary Fluorine Cosmic Rays: Results from the Alpha Magnetic Spectrometer

11. Properties of Iron Primary Cosmic Rays: Results from the Alpha Magnetic Spectrometer

12. Properties of Neon, Magnesium, and Silicon Primary Cosmic Rays Results from the Alpha Magnetic Spectrometer

13. Properties of Cosmic Helium Isotopes Measured by the Alpha Magnetic Spectrometer

16. Towards Understanding the Origin of Cosmic-Ray Electrons

17. Towards Understanding the Origin of Cosmic-Ray Positrons

18. Observation of Complex Time Structures in the Cosmic-Ray Electron and Positron Fluxes with the Alpha Magnetic Spectrometer on the International Space Station

19. Precision Measurement of Cosmic-Ray Nitrogen and its Primary and Secondary Components with the Alpha Magnetic Spectrometer on the International Space Station

20. Observation of Fine Time Structures in the Cosmic Proton and Helium Fluxes with the Alpha Magnetic Spectrometer on the International Space Station

21. Observation of New Properties of Secondary Cosmic Rays Lithium, Beryllium, and Boron by the Alpha Magnetic Spectrometer on the International Space Station

22. Observation of the Identical Rigidity Dependence of He, C, and O Cosmic Rays at High Rigidities by the Alpha Magnetic Spectrometer on the International Space Station

23. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)

24. Transcriptome and metabolome analyses of the immune response to light stress in the hybrid grouper (Epinephelus lanceolatus ♂ × Epinephelus fuscoguttatus ♀)

25. Observation of Z>2 trapped nuclei by AMS on ISS

26. Precision Measurement of the Boron to Carbon Flux Ratio in Cosmic Rays from 1.9 GV to 2.6 TV with the Alpha Magnetic Spectrometer on the International Space Station

27. Antiproton Flux, Antiproton-to-Proton Flux Ratio, and Properties of Elementary Particle Fluxes in Primary Cosmic Rays Measured with the Alpha Magnetic Spectrometer on the International Space Station

28. Precision Measurement of the Helium Flux in Primary Cosmic Rays of Rigidities 1.9 GV to 3 TV with the Alpha Magnetic Spectrometer on the International Space Station

29. Precision Measurement of the Proton Flux in Primary Cosmic Rays from Rigidity 1 GV to 1.8 TV with the Alpha Magnetic Spectrometer on the International Space Station

30. 272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)

31. Abstract P6-18-04: Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis

32. Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

33. Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

34. Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer

35. Precision Measurement of the(e++e−)Flux in Primary Cosmic Rays from 0.5 GeV to 1 TeV with the Alpha Magnetic Spectrometer on the International Space Station

36. 309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1

37. First Result from the Alpha Magnetic Spectrometer on the International Space Station: Precision Measurement of the Positron Fraction in Primary Cosmic Rays of 0.5–350 GeV

38. Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)

39. Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

40. 330P Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2− advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)

41. 329P Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials

42. LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)

43. 93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

44. Abstract OT1-04-03: Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)

45. Abstract P4-22-12: Ribociclib + fulvestrant in postmenopausal women with HR+, HER2– advanced breast cancer (ABC)

46. 47MO Efficacy and quality of life (QOL) in premenopausal Asian patients (pts) with hormone receptor–positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated in the MONALEESA (ML)-7 study

47. 301P Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for alpelisib (ALP)-induced hyperglycemia: A report of 6 cases from SOLAR-1

48. Abstract P4-14-23: A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer

49. Abstract P4-13-27: A phase Ib dose de-escalation study of combined tamoxifen and goserelin acetate with alpelisib (BYL719) or buparlisib (BKM120) in premenopausal patients with HR+/HER2– locally advanced or metastatic breast cancer

50. Search for a Higgs boson decaying into two photons in e(+)e(-) interactions at root s=189 GeV